Skip to main content
WoMWeb of Medicine
SearchGraphHistory
Cardiology›Condition·Updated Jul 11, 2026·v1

Beta-Adrenergic Blockers

Beta-adrenergic blockers are a diverse class of drugs with broad cardiovascular and non-cardiovascular indications. Their use requires careful agent selection based on receptor selectivity, pharmacokinetics, and patient comorbidities. The steep dose-response in HFrEF mandates aggressive titration to target doses. Adverse effects include bradycardia, hypotension, metabolic disturbances, and fetal growth restriction. Drug interactions with NSAIDs and CYP2D6 inhibitors are clinically significant. Monitoring of heart rate, blood pressure, and symptoms is essential.

High Evidence67 references·2,347 words·10 min read·v1
beta-blockersbeta-adrenergic antagonistscardiovascular pharmacologyheart failurehypertensionarrhythmiasinfantile hemangiomasportal hypertensionmigraineessential tremor

Quick Reference

RxDrug of choiceFor HFrEF: bisoprolol, carvedilol, metoprolol succinate. For infantile hemangiomas: propranolol. For migraine/essential tremor: propranolol. For portal hypertension: propranolol or nadolol.
AltAlternativesFor hypertension: CCBs, ACEIs, ARBs. For HFrEF: ARNI, SGLT2i, MRA. For glaucoma: prostaglandin analogs, carbonic anhydrase inhibitors.
⊘AvoidSevere bradycardia (HR <45 bpm), second/third-degree AV block without pacemaker, decompensated HF (NYHA IV, acute pulmonary edema), cardiogenic shock, severe asthma with active bronchospasm, hypersensitivity.
DxTest of choiceEchocardiography for HFrEF; ECG for arrhythmias; sST2 biomarker for dose optimization in HF; spirometry for COPD/asthma baseline.
ScKey scoreNYHA class for HF; CHA2DS2-VASc for AF; HEART score for chest pain.
→When to referFor HFrEF not tolerating up-titration, consider cardiology; for refractory arrhythmias, electrophysiology; for infantile hemangiomas not responding, dermatology; for complex polypharmacy, clinical pharmacology.
Beta-blockers are essential in HFrEF and post-MI, with steep dose-response; titrate to target doses (metoprolol succinate 200 mg, carvedilol 25 mg BID, bisoprolol 10 mg). Avoid in decompensated HF and severe asthma; monitor for bradycardia, hypotension, and metabolic effects. Agent selection matters: cardioselective for COPD, nonselective for portal hypertension, avoid atenolol/propranolol in pregnancy.
Beta-adrenergic blockers (beta-blockers) are a cornerstone of cardiovascular pharmacotherapy, used in hypertension, heart failure, arrhythmias, and post-MI. They competitively antagonize beta-adrenergic receptors, reducing sympathetic tone. Classification by receptor selectivity (cardioselective β1 vs nonselective β1/β2) and additional properties (alpha-blockade, lipophilicity) determines clinical use and side-effect profile. Key agents include propranolol, metoprolol, carvedilol, and bisoprolol.

Overview and Recommendations

Key Facts

  • •Beta-adrenergic blockers competitively antagonize β1 and/or β2 receptors, reducing cAMP generation and blunting sympathetic response. Cardioselective agents (e.g., , ) preferentially block β1, while nonselective agents (e.g., ) block both β1 and β2, making them useful for portal hypertension and essential tremor but riskier in asthma.
  • •In HFrEF (LVEF ≤40%), beta-blockers reduce mortality and hospitalizations; the dose-response is steep, with target doses from landmark trials (metoprolol succinate 200 mg daily, carvedilol 25 mg BID, bisoprolol 10 mg daily) associated with incremental benefit beyond heart rate reduction alone.
  • •Beta-blockers slow progression of coronary atherosclerosis (mean annual change in atheroma volume -2.4 mm³/y vs -0.4 mm³/y untreated, P=0.034) and reduce sudden cardiac death post-MI. Over 70% of patients receive beta-blockers at discharge after acute MI.
  • •Beyond cardiovascular indications, beta-blockers are first-line for infantile hemangiomas (propranolol ≥2 mg/kg/day), migraine prophylaxis, essential tremor, and portal hypertension (nonselective agents for variceal prevention). They also reduce fracture risk by 15% (pooled ES 0.86), possibly via β1-receptors on bone cells.
  • •Pharmacogenomic variability (CYP2D6 polymorphisms) affects metabolism of metoprolol, carvedilol, and propranolol, leading to interindividual differences in response and toxicity. This is especially relevant in elderly patients and those on multiple medications.
  • •Beta-blockers are associated with a 15% reduction in fracture risk (pooled ES 0.86), an effect more pronounced with β1-selective agents. The mechanism may involve β1-receptors on osteoblasts and osteoclasts.

Clinical Use

  • •Initiate beta-blocker therapy for HFrEF (LVEF ≤40%) with 1.25 mg daily, 3.125 mg BID, or 12.5-25 mg daily; titrate every 2-4 weeks to target doses (bisoprolol 10 mg daily, carvedilol 25 mg BID, metoprolol succinate 200 mg daily) or maximally tolerated dose. Use sST2 ≤35 ng/mL to identify patients who benefit most from high-dose therapy.
  • •In post-MI patients, start beta-blocker within 24 hours if hemodynamically stable; continue indefinitely for secondary prevention. Target resting heart rate 55-60 bpm.
  • •For rate control in atrial fibrillation, use 25-100 mg BID or 25-100 mg daily; target resting heart rate <80 bpm. Pretreatment with oral beta-blockers increases success of intravenous cibenzoline for termination of postoperative AF (OR 8.224, P=0.030).
  • •In hypertension, reserve beta-blockers for patients with concomitant CAD, HF, or prior MI; avoid as first-line monotherapy due to inferior stroke prevention vs CCBs (OR 0.79 for CCBs). Vasodilating beta-blockers like may have less adverse effect on central blood pressure.
  • •For infantile hemangiomas, administer 2-3 mg/kg/day divided TID; start at 1 mg/kg/day and escalate over 2-3 weeks. Propranolol is more effective than systemic steroids (OR 0.92) and safer.
  • •In portal hypertension, use 20-160 mg BID or 40-160 mg daily to reduce hepatic venous pressure gradient; titrate to heart rate reduction of 25% or to 55-60 bpm. Do not use for primary prevention of varices in compensated cirrhosis without varices.
  • •For migraine prophylaxis, start 40 mg BID or 50 mg BID; titrate to 80-160 mg daily for propranolol or 100-200 mg daily for metoprolol. A 3-month trial is typical.
  • •In essential tremor, initiate 20 mg BID, titrate to 40-120 mg daily; avoid in patients with asthma or heart block.
  • •For thyrotoxicosis symptom control, use 40-80 mg every 6-8 hours; adjust based on heart rate.
  • •In Marfan syndrome, start 25-50 mg daily; titrate to heart rate <60 bpm at rest to slow aortic root dilation. offers additional antistiffness effects.
  • •For perioperative cardiac risk reduction, do not initiate high-dose beta-blockade in beta-blocker-naïve patients; continue existing therapy but avoid starting on day of surgery. Perioperative beta-blockade does not reduce mortality or non-fatal MI in vascular surgery (OR 0.62 and 0.83, respectively).
  • •In glaucoma, use 0.25-0.5% ophthalmic solution BID; note that prostaglandin analog + beta-blocker combinations show pharmacological antagonism (1.26 mmHg less IOP reduction). Non-PGFA triple combinations (alpha-agonist + beta-blocker + CAI) are a useful alternative.
  • •For catecholaminergic polymorphic ventricular tachycardia (CPVT), use 2-4 mg/kg/day; consider adding if inadequate control, as combination markedly enhances protection in CASQ2-mutant models.
  • •In pregnancy, avoid and due to high risk of fetal growth restriction (33% and 36%, respectively); prefer (0% FGR) or if beta-blockade is necessary. Use lowest effective dose and monitor fetal growth with serial ultrasound.
  • •For acute ischemic stroke requiring IV antihypertensives, continuous infusion (starting 0.5-2 mg/min) is comparable to nicardipine for blood pressure control (time in goal 68% vs 67%).
  • •When discontinuing beta-blockers, taper gradually over 1-2 weeks to avoid rebound hypertension, tachycardia, and myocardial ischemia. Abrupt withdrawal can cause a withdrawal syndrome.

Safety

  • •Suspect beta-blocker overdose when a patient presents with bradycardia, hypotension, and altered mental status; ECG may show AV block (first, second, or third degree) or ventricular arrhythmias. Treatment includes glucagon, high-dose insulin euglycemia, and transvenous pacing for refractory cases.
  • •Assess for bradycardia (HR <50 bpm) and hypotension (SBP <100 mmHg) at each visit; reduce dose if symptomatic. In elderly patients, start at half the usual dose and titrate slowly to minimize falls.
  • •Monitor for bronchospasm in patients with asthma or COPD; prefer cardioselective agents ( , ) and start at low doses. Even cardioselective agents can provoke bronchospasm in susceptible individuals.
  • •Evaluate for signs of heart failure exacerbation (dyspnea, edema, weight gain) during initiation and up-titration; if worsening occurs, reduce diuretic dose first before reducing beta-blocker. Beta-blockers can exacerbate HF in patients with marginal cardiac reserve.
  • •In patients with diabetes, monitor for masked hypoglycemia symptoms; beta-blockers blunt tachycardia and palpitations but not sweating. Advise more frequent capillary glucose monitoring during dose titration.
  • •Check renal function and electrolytes before starting; renally cleared agents ( , ) require dose adjustment for eGFR <30 mL/min. Hepatically cleared agents ( , ) may accumulate in cirrhosis.
  • •In pregnancy, perform serial fetal ultrasound to monitor for growth restriction; avoid and (FGR rates 33% and 36%). and appear safer (0% and no association). Beta-blockers are also associated with lower birth weight and insufficient gestational weight gain.
  • •Assess for depression, especially with ; 12 of 24 case reports had Naranjo score ≥5 suggesting likely causality. Inquire about mood changes after initiation or dose increase, particularly in patients with prior depression.
  • •Avoid abrupt withdrawal; taper over 1-2 weeks to prevent rebound hypertension, tachycardia, and myocardial ischemia. Rebound can occur even after short-term therapy.
  • •For patients on NSAIDs (e.g., ), anticipate reduced antihypertensive efficacy; monitor blood pressure after >5 days of concomitant use. NSAID-related loss of BP control can lead to substantial cardiovascular events.
  • •In glaucoma patients on topical beta-blockers, be aware of systemic absorption; monitor heart rate and pulmonary function. Systemic effects are more common with nonselective agents like .
  • •For patients undergoing surgery while on beta-blockers, continue therapy perioperatively; use processed EEG monitors (BIS, PSI) to guide anesthetic depth as beta-blockers blunt hemodynamic signs of inadequate anesthesia. This reduces fentanyl use without prolonging extubation time.

Board Review — High Yield

  • •Steep dose-response in HFrEF, Incremental mortality benefit with dose escalation beyond heart rate reduction; target doses from trials (metoprolol succinate 200 mg, carvedilol 25 mg BID, bisoprolol 10 mg) are critical.
  • •Cardioselectivity, β1-selective agents (metoprolol, bisoprolol) preferred in COPD/asthma; nonselective (propranolol) used for portal hypertension, essential tremor, migraine.
  • •Fetal growth restriction, Risk varies: atenolol 33%, propranolol 36%, metoprolol 17%, bisoprolol 0%; carvedilol appears safe.
  • •NSAID interaction, Ibuprofen and other NSAIDs reduce antihypertensive efficacy; monitor BP after >5 days of concomitant use.
  • •Propranolol and depression, 12 of 24 case reports had Naranjo score ≥5; depression onset soon after starting; inquire about mood.
  • •Perioperative beta-blockade, Do not initiate high-dose in beta-blocker-naïve patients; continue existing therapy.
  • •sST2 biomarker, Low sST2 (≤35 ng/mL) identifies patients who benefit most from high-dose beta-blocker in HFrEF.
  • •Glaucoma antagonism, PGFA + beta-blocker combination reduces IOP less than additive; avoid this combination.
  • •Overdose treatment, Glucagon, high-dose insulin euglycemia, transvenous pacing for severe beta-blocker overdose.
  • •Rebound phenomenon, Abrupt withdrawal can cause hypertension, tachycardia, myocardial ischemia; taper over 1-2 weeks.

Deep Dive — Evidence Details

References

  1. [1]

    Steffensmeier JJ, Ernst ME, Kelly M et al.. “Do randomized controlled trials always trump case reports? A second look at propranolol and depression.” Pharmacotherapy (2006). PMID: 16466322 ↗

    L2SR_MA_RCTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  2. [2]

    Rasmussen ER, Pottegård A, Bygum A et al.. “Angiotensin II receptor blockers are safe in patients with prior angioedema related to angiotensin-converting enzyme inhibitors - a nationwide registry-based cohort study.” Journal of internal medicine (2019). PMID: 30618189 ↗

    L2COHORTCited in: Introduction and Chemical Structure, Adverse Effects and Toxicity
  3. [3]

    Guglielmi P, Carradori S, Campestre C et al.. “Novel therapies for glaucoma: a patent review (2013-2019).” Expert opinion on therapeutic patents (2019). PMID: 31385719 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
  4. [4]

    Pekic S, Jovanovic V, Tasic G et al.. “Intracerebral hemorrhage as a first sign of pheochromocytoma: case report and review of the literature.” Endokrynologia Polska (2018). PMID: 30351443 ↗

    L4CASE_REPORTCited in: Introduction and Chemical Structure
  5. [5]

    Sipahi I, Tuzcu EM, Wolski KE et al.. “Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials.” Annals of internal medicine (2007). PMID: 17606956 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  6. [6]

    Auerbach DS, Biton Y, Polonsky B et al.. “Risk of cardiac events in Long QT syndrome patients when taking antiseizure medications.” Translational research : the journal of laboratory and clinical medicine (2017). PMID: 29121487 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  7. [7]

    Zheng Z, Chen H, Xu X et al.. “Effects of angiotensin-converting enzyme inhibitors and beta-adrenergic blockers on retinal vascular endothelial growth factor expression in rat diabetic retinopathy.” Experimental eye research (2006). PMID: 17303121 ↗

    L5OTHERCited in: Introduction and Chemical Structure
  8. [8]

    Valdes AM, Abhishek A, Muir K et al.. “Association of Beta-Blocker Use With Less Prevalent Joint Pain and Lower Opioid Requirement in People With Osteoarthritis.” Arthritis care & research (2017). PMID: 27696728 ↗

    L2OTHERCited in: Introduction and Chemical Structure
  9. [9]

    Cambou JP, Simon T, Mulak G et al.. “The French registry of Acute ST elevation or non-ST-elevation Myocardial Infarction (FAST-MI): study design and baseline characteristics.” Archives des maladies du coeur et des vaisseaux (2007). PMID: 17893635 ↗

    L2TRIAL_NONRANDOMCited in: Introduction and Chemical Structure
  10. [10]

    Márquez MF, Gómez-Flores JR, González-Hermosillo JA et al.. “Role of the sympathetic nervous system in vasovagal syncope and rationale for beta-blockers and norepinephrine transporter inhibitors.” Medwave (2016). PMID: 28055999 ↗

    L5REVIEW_NARRATIVECited in: Introduction and Chemical Structure
  11. [11]

    Dobaczewski M, Chen W, Frangogiannis NG. “Transforming growth factor (TGF)-β signaling in cardiac remodeling.” Journal of molecular and cellular cardiology (2010). PMID: 21059352 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  12. [12]

    Ricon I, Hanalis-Miller T, Haldar R et al.. “Perioperative biobehavioral interventions to prevent cancer recurrence through combined inhibition of β-adrenergic and cyclooxygenase 2 signaling.” Cancer (2018). PMID: 30291805 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action, Drug Interactions
  13. [13]

    Obeid EI, Conzen SD. “The role of adrenergic signaling in breast cancer biology.” Cancer biomarkers : section A of Disease markers (2013). PMID: 23912488 ↗

    L5REVIEW_NARRATIVECited in: Mechanism of Action
  14. [14]

    Cecilio HP, Valente VB, Pereira KM et al.. “Beta-adrenergic blocker inhibits oral carcinogenesis and reduces tumor invasion.” Cancer chemotherapy and pharmacology (2020). PMID: 32980903 ↗

    L5OTHERCited in: Mechanism of Action, Adverse Effects and Toxicity
  15. [15]

    Ghosh PM, Shu ZJ, Zhu B et al.. “Role of β-adrenergic receptors in regulation of hepatic fat accumulation during aging.” The Journal of endocrinology (2012). PMID: 22457517 ↗

    L5OTHERCited in: Mechanism of Action
  16. [16]

    Sung RJ, Wu YH, Lai NH et al.. “Beta-adrenergic modulation of arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in Timothy (LQT8) syndrome: a theoretical study.” American journal of physiology. Heart and circulatory physiology (2009). PMID: 19855067 ↗

    L5OTHERCited in: Mechanism of Action
  17. [17]

    Parati G, Esler M. “The human sympathetic nervous system: its relevance in hypertension and heart failure.” European heart journal (2012). PMID: 22507981 ↗

    L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
  18. [18]

    Höcht C, Bertera FM, Mayer MA et al.. “Issues in drug metabolism of major antihypertensive drugs: beta-blockers, calcium channel antagonists and angiotensin receptor blockers.” Expert opinion on drug metabolism & toxicology (2010). PMID: 20095790 ↗

    L5REVIEW_NARRATIVECited in: Resistance and Pharmacogenomics
  19. [19]

    Melnik BC. “Permanent impairment of insulin resistance from pregnancy to adulthood: the primary basic risk factor of chronic Western diseases.” Medical hypotheses (2009). PMID: 19515499 ↗

    L5OTHERCited in: Resistance and Pharmacogenomics
  20. [20]

    Aronow WS, Frishman WH, Cheng-Lai A. “Cardiovascular drug therapy in the elderly.” Cardiology in review (2007). PMID: 17575484 ↗

    L5REVIEW_NARRATIVECited in: Pharmacokinetics (LADME), Drug Interactions
  21. [21]

    Gaggin HK, Motiwala S, Bhardwaj A et al.. “Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure.” Circulation. Heart failure (2013). PMID: 24114865 ↗

    L2RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification
  22. [22]

    Olshansky B, Sullivan RM. “Inappropriate sinus tachycardia.” Journal of the American College of Cardiology (2012). PMID: 23265330 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics
  23. [23]

    Bhatt AS, DeVore AD, DeWald TA et al.. “Achieving a Maximally Tolerated β-Blocker Dose in Heart Failure Patients: Is There Room for Improvement?” Journal of the American College of Cardiology (2017). PMID: 28521892 ↗

    L5REVIEW_NARRATIVECited in: Pharmacodynamics, Dose and Administration, Dose Modification
  24. [24]

    Park JM, Mun JH, Song M et al.. “Propranolol, doxycycline and combination therapy for the treatment of rosacea.” The Journal of dermatology (2014). PMID: 25389041 ↗

    L2TRIAL_NONRANDOMCited in: Pharmacodynamics
  25. [25]

    Chen J, Runyan SA, Robinson MR. “Novel ocular antihypertensive compounds in clinical trials.” Clinical ophthalmology (Auckland, N.Z.) (2011). PMID: 21629573 ↗

    L5TRIAL_NONRANDOMCited in: Pharmacodynamics
  26. [26]

    Hsia Y, Wang C, Su CC et al.. “Efficacy and Drug Interactions of Glaucoma Medications: A Systematic Review and Component Network Meta-analysis.” Ophthalmology (2025). PMID: 40701331 ↗

    L1SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Drug Interactions
  27. [27]

    Logger JGM, Olydam JI, Driessen RJB. “Use of beta-blockers for rosacea-associated facial erythema and flushing: A systematic review and update on proposed mode of action.” Journal of the American Academy of Dermatology (2020). PMID: 32360760 ↗

    L2SR_OBSCited in: Pharmacodynamics, Adverse Effects and Toxicity
  28. [28]

    Toulis KA, Hemming K, Stergianos S et al.. “β-Adrenergic receptor antagonists and fracture risk: a meta-analysis of selectivity, gender, and site-specific effects.” Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA (2013). PMID: 24114396 ↗

    L2SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification
  29. [29]

    Brewster LM, Seedat YK. “Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review.” BMC medicine (2013). PMID: 23721258 ↗

    L2SR_OBSCited in: Pharmacodynamics
  30. [30]

    Komatsu T, Tachibana H, Satoh Y et al.. “Prospective comparative study of intravenous cibenzoline and disopyramide therapy in the treatment of paroxysmal atrial fibrillation after cardiovascular surgery.” Circulation journal : official journal of the Japanese Circulation Society (2010). PMID: 20631453 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  31. [31]

    Haseeb ME, Mohammed HE, Yaser H et al.. “Unveiling the efficacy and safety of Erenumab, a monoclonal antibody targeting calcitonin gene-related peptide (CGRP) receptor, in patients with chronic and episodic migraine: a GRADE-assessed systematic review and meta-analysis of randomized clinical trials with subgroup analysis.” Head & face medicine (2025). PMID: 40134001 ↗

    L1SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use
  32. [32]

    Li L, Jiang Z, Li L et al.. “Impact of Various Doses of Dobutamine on Myocardial Viability and the Effects of β-Blockers in Patients With Ischemic Cardiomyopathy: An Assessment Using Stress Echocardiography.” Echocardiography (Mount Kisco, N.Y.) (2025). PMID: 40152925 ↗

    L1RCTCited in: Pharmacodynamics, Indications and Clinical Use, Dose and Administration, Dose Modification
  33. [33]

    Mostafaie K, Bedenis R, Harrington D. “Beta-adrenergic blockers for perioperative cardiac risk reduction in people undergoing vascular surgery.” The Cochrane database of systematic reviews (2015). PMID: 25879091 ↗

    L1SR_OBSCited in: Pharmacodynamics, Indications and Clinical Use, Adverse Effects and Toxicity
  34. [34]

    Ward F, Tharian P, Roy M et al.. “Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review.” Research in developmental disabilities (2013). PMID: 24171827 ↗

    L4SR_OBSCited in: Pharmacodynamics
  35. [35]

    Coleman CI, Baker WL, Kluger J et al.. “Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials.” Journal of hypertension (2008). PMID: 18327066 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  36. [36]

    Abraldes JG, Albillos A, Bañares R et al.. “Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.” Gastroenterology (2009). PMID: 19208350 ↗

    L1RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  37. [37]

    Reverter E, Mesonero F, Seijo S et al.. “Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.” The American journal of gastroenterology (2015). PMID: 26077176 ↗

    L1RCTCited in: Indications and Clinical Use, Dose and Administration, Dose Modification
  38. [38]

    Garcia-Tsao G. “Preventing the development of varices in cirrhosis.” Journal of clinical gastroenterology (2007). PMID: 17975480 ↗

    L5RCTCited in: Indications and Clinical Use, Adverse Effects and Toxicity
  39. [39]

    Gambarin FI, Favalli V, Serio A et al.. “Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations.” Journal of cardiovascular medicine (Hagerstown, Md.) (2009). PMID: 19430350 ↗

    L5RCTCited in: Indications and Clinical Use, Special Populations and Contraindications
  40. [40]

    Drover DR, Schmiesing C, Buchin AF et al.. “Titration of sevoflurane in elderly patients: blinded, randomized clinical trial, in non-cardiac surgery after beta-adrenergic blockade.” Journal of clinical monitoring and computing (2011). PMID: 21830049 ↗

    L1RCTCited in: Indications and Clinical Use, Monitoring and Follow-up
  41. [41]

    Palming J, Jansson PA, Renström F et al.. “Hydrochlorothiazide compared to candesartan treatment increases adipose tissue gene expression and circulating levels of serum amyloid A in hypertensive patients.” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2011). PMID: 21332024 ↗

    L1RCTCited in: Indications and Clinical Use
  42. [42]

    Vyas A, Swaminathan PD, Zimmerman MB et al.. “Are treatments for vasovagal syncope effective? A meta-analysis.” International journal of cardiology (2012). PMID: 22626839 ↗

    L2SR_OBSCited in: Indications and Clinical Use
  43. [43]

    Pucci G, Ranalli MG, Battista F et al.. “Effects of β-Blockers With and Without Vasodilating Properties on Central Blood Pressure: Systematic Review and Meta-Analysis of Randomized Trials in Hypertension.” Hypertension (Dallas, Tex. : 1979) (2015). PMID: 26628678 ↗

    L1SR_OBSCited in: Indications and Clinical Use
  44. [44]

    Chen GJ, Yang MS. “The effects of calcium channel blockers in the prevention of stroke in adults with hypertension: a meta-analysis of data from 273,543 participants in 31 randomized controlled trials.” PloS one (2013). PMID: 23483932 ↗

    L1SR_MA_RCTCited in: Indications and Clinical Use
  45. [45]

    Liu X, Qu X, Zheng J et al.. “Effectiveness and Safety of Oral Propranolol versus Other Treatments for Infantile Hemangiomas: A Meta-Analysis.” PloS one (2015). PMID: 26375455 ↗

    L2SR_OBSCited in: Indications and Clinical Use
  46. [46]

    Packer M. “Inferential characterization of the dose-response relationships of neurohormonal antagonists in chronic heart failure: A novel approach based on large-scale trials with active comparators.” International journal of cardiology (2018). PMID: 29548536 ↗

    L5REVIEW_NARRATIVECited in: Dose and Administration, Dose Modification
  47. [47]

    Dzialowski EM, Turner PK, Brooks BW. “Physiological and reproductive effects of beta adrenergic receptor antagonists in Daphnia magna.” Archives of environmental contamination and toxicology (2006). PMID: 16583257 ↗

    L5OTHERCited in: Dose and Administration, Dose Modification, Adverse Effects and Toxicity
  48. [48]

    Hecht JP, Richards PG. “Continuous-Infusion Labetalol vs Nicardipine for Hypertension Management in Stroke Patients.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2017). PMID: 29092768 ↗

    L3OTHERCited in: Dose and Administration
  49. [49]

    Knudsen MB, Thøgersen AM, Hjortshøj SP et al.. “The impact of drug discontinuation in patients treated with temporary pacemaker due to atrioventricular block.” Journal of cardiovascular electrophysiology (2013). PMID: 23869746 ↗

    L4OTHERCited in: Dose and Administration
  50. [50]

    Milic M, Ziegler MG. “Discrepant antihypertensive dose recommendations.” Clinical and experimental hypertension (New York, N.Y. : 1993) (2006). PMID: 16546842 ↗

    L5CASE_REPORTCited in: Dose and Administration, Dose Modification
  51. [51]

    Cooper-DeHoff RM, Pacanowski MA, Pepine CJ. “Cardiovascular therapies and associated glucose homeostasis: implications across the dysglycemia continuum.” Journal of the American College of Cardiology (2009). PMID: 19179214 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  52. [52]

    Jung W, Meyerfeldt U, Birkemeyer R. “Atrial arrhythmias after cardiac surgery in patients with diabetes mellitus.” Clinical research in cardiology : official journal of the German Cardiac Society (2006). PMID: 16598557 ↗

    L1SR_OBSCited in: Adverse Effects and Toxicity
  53. [53]

    Walz MS, Sabry AA, Antony KM. “Gestational weight gain in pregnancies complicated by chronic hypertension treated with beta-blockers or calcium channel blockers versus unmedicated pregnancies: A retrospective cohort study from the PeriBank database.” Pregnancy hypertension (2025). PMID: 40516391 ↗

    L2COHORTCited in: Adverse Effects and Toxicity, Special Populations and Contraindications
  54. [54]

    Williamson DR, Frenette AJ, Burry L et al.. “Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis.” Systematic reviews (2016). PMID: 27855720 ↗

    L5SR_OBSCited in: Adverse Effects and Toxicity, Special Populations and Contraindications
  55. [55]

    Minhas S, Khan A, Naids S et al.. “Cardiovascular Events After Partner Bereavement, What is the Role of Low Dose Aspirin and Beta-Blockers?” Current problems in cardiology (2021). PMID: 34103192 ↗

    L5SR_OBSCited in: Adverse Effects and Toxicity
  56. [56]

    Delk C, Holstege CP, Brady WJ. “Electrocardiographic abnormalities associated with poisoning.” The American journal of emergency medicine (2007). PMID: 17606094 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  57. [57]

    Fleg JL, Aronow WS, Frishman WH. “Cardiovascular drug therapy in the elderly: benefits and challenges.” Nature reviews. Cardiology (2010). PMID: 20978470 ↗

    L5REVIEW_NARRATIVECited in: Adverse Effects and Toxicity
  58. [58]

    Tanaka K, Tanaka H, Kamiya C et al.. “Beta-Blockers and Fetal Growth Restriction in Pregnant Women With Cardiovascular Disease.” Circulation journal : official journal of the Japanese Circulation Society (2016). PMID: 27593227 ↗

    L2OTHERCited in: Adverse Effects and Toxicity, Special Populations and Contraindications
  59. [59]

    Macías-Pérez JR, Vázquez-López BJ, Muñoz-Ortega MH et al.. “Curcumin and α/β-Adrenergic Antagonists Cotreatment Reverse Liver Cirrhosis in Hamsters: Participation of Nrf-2 and NF-κB.” Journal of immunology research (2019). PMID: 31183386 ↗

    L5OTHERCited in: Adverse Effects and Toxicity, Drug Interactions
  60. [60]

    Salort-Llorca C, Mínguez-Serra MP, Silvestre-Donat FJ. “Interactions between ibuprofen and antihypertensive drugs: incidence and clinical relevance in dental practice.” Medicina oral, patologia oral y cirugia bucal (2008). PMID: 18978713 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  61. [61]

    Veverka A, Nuzum DS, Jolly JL. “Nebivolol: a third-generation beta-adrenergic blocker.” The Annals of pharmacotherapy (2006). PMID: 16822893 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  62. [62]

    Desai MY, Michaud V, Thacker D et al.. “CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitors.” Expert opinion on drug safety (2025). PMID: 41313044 ↗

    L5REVIEW_NARRATIVECited in: Drug Interactions
  63. [63]

    Katz G, Khoury A, Kurtzwald E et al.. “Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.” Heart rhythm (2010). PMID: 20620233 ↗

    L5TRIAL_NONRANDOMCited in: Special Populations and Contraindications
  64. [64]

    Giouleme O, Theocharidou E. “Management of portal hypertension in children with portal vein thrombosis.” Journal of pediatric gastroenterology and nutrition (2013). PMID: 23820400 ↗

    L5REVIEW_NARRATIVECited in: Special Populations and Contraindications
  65. [65]

    Zatzick D, Roy-Byrne PP. “From bedside to bench: how the epidemiology of clinical practice can inform the secondary prevention of PTSD.” Psychiatric services (Washington, D.C.) (2006). PMID: 17158486 ↗

    L2OTHERCited in: Special Populations and Contraindications
  66. [66]

    Zahalka AH, Fram E, Garden E et al.. “Association between beta-blocker atenolol use and prostate cancer upgrading in active surveillance.” BJUI compass (2024). PMID: 39539558 ↗

    L2OTHERCited in: Monitoring and Follow-up
  67. [67]

    Eagleman SL, Drover CM, Li X et al.. “Offline comparison of processed electroencephalogram monitors for anaesthetic-induced electroencephalogram changes in older adults.” British journal of anaesthesia (2021). PMID: 33640118 ↗

    L5OTHERCited in: Monitoring and Follow-up

Revision History

All updates applied to this page

Loading revisions…